-
公开(公告)号：US10940198B2
公开(公告)日：2021-03-09
申请号：US16473393
申请日：2017-12-20
发明人： Hyo Jung Nam , Eun Mi Kim , Duck Hyang Shin , Steven G. Reed , Kang Il Yoo , Sung Jun Hong
IPC分类号： A61K39/25 , A61P31/22 , A61K31/7024 , A61K31/01 , A61K39/00 , A61K39/39 , G01N33/569
摘要： The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
-
公开(公告)号：US09907845B2
公开(公告)日：2018-03-06
申请号：US14096582
申请日：2013-12-04
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/395 , A61K39/39 , A61K9/107 , A61K39/00 , A61K39/35 , A61K45/06 , A61K39/008 , A61K39/04 , A61K39/145
CPC分类号： A61K39/39 , A61K9/107 , A61K39/0011 , A61K39/008 , A61K39/04 , A61K39/145 , A61K39/35 , A61K45/06 , A61K2039/55511 , A61K2039/55572 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/41 , Y02A50/491
摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
3.发明申请COMPOSITIONS AND METHODS FOR TREATING AN ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION 审中-公开用于治疗活动性MYCOBACTERIUM TUBCCOSOSIS感染的组合物和方法公开(公告)号：US20150182612A1
公开(公告)日：2015-07-02
申请号：US14419477
申请日：2013-08-02
发明人： Steven G. Reed , Rhea N. Coler
CPC分类号： A61K39/04 , A61K31/4409 , A61K31/496 , A61K39/39 , A61K45/06 , A61K2039/545 , A61K2039/55511 , A61K2039/70 , A61K2300/00
摘要： The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.
摘要翻译： 本公开涉及用于治疗活动性结核感染的方法和组合物，以及用于改善针对活动性结核感染的化疗方案的功效的方法和组合物。 本公开涉及治疗活动性结核分枝杆菌感染或由哺乳动物的潜伏感染的再活化引起的活性感染的方法以及提高针对活动性结核分枝杆菌感染的化学疗法疗效的方法。
-
4.发明申请ADJUVANT FORMULATIONS COMPRISING TLR4 AGONISTS AND METHODS OF USING THE SAME 审中-公开包含TLR4激动剂的补充剂配方及其使用方法公开(公告)号：US20150017191A1
公开(公告)日：2015-01-15
申请号：US14377488
申请日：2013-02-07
发明人： Christopher Fox , Steven G. Reed , Susan Baldwin , Thomas Vedvick
摘要： Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.
摘要翻译： 公开了制剂和方法，包括用于诱导或增强免疫应答的疫苗和药物组合物。 制剂通常包含浓度为约0.01％-1％v / v的TLR4激动剂和可代谢的油，其中乳液的疏水性：亲油平衡（HLB）大于约9。
-
5.发明授权公开(公告)号：US11091521B2
公开(公告)日：2021-08-17
申请号：US15815512
申请日：2017-11-16
IPC分类号： C07K14/35 , A61K39/04 , C07K14/285 , A61K39/00 , G01N33/569 , G01N33/68
摘要： The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
-
公开(公告)号：US09987355B2
公开(公告)日：2018-06-05
申请号：US13930953
申请日：2013-06-28
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/39 , A61K9/107 , A61K39/00 , A61K39/35 , A61K45/06 , A61K39/008 , A61K39/04 , A61K39/145
CPC分类号： A61K39/39 , A61K9/107 , A61K39/0011 , A61K39/008 , A61K39/04 , A61K39/145 , A61K39/35 , A61K45/06 , A61K2039/55511 , A61K2039/55572 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/41 , Y02A50/491
摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
7.发明授权Fusion proteins and their use in the diagnosis and treatment of leishmaniasis 有权融合蛋白及其在利什曼病诊断和治疗中的应用公开(公告)号：US09279005B2
公开(公告)日：2016-03-08
申请号：US14286647
申请日：2014-05-23
发明人： Ajay Bhatia , Steven G. Reed
IPC分类号： G01N33/569 , C12P21/04 , A61K39/008 , C07K14/44 , G01N33/68 , C07K16/20 , A61K38/00 , A61K39/00
CPC分类号： C07K14/44 , A61K38/00 , A61K39/00 , C07K16/20 , G01N33/56905 , G01N33/6893 , Y10S435/81 , Y10S435/975
摘要： The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
摘要翻译： 本发明一般涉及由包含源自利什曼原虫抗原K26，K39和K9的元件的合成基因构建体制成的融合蛋白。 融合蛋白特别可用于诊断利什曼病，特别是动物如人和狗中的内脏利什曼病。
-
公开(公告)号：US10765736B2
公开(公告)日：2020-09-08
申请号：US15823852
申请日：2017-11-28
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/395 , A61K39/39 , A61K9/107 , A61K39/00 , A61K39/35 , A61K45/06 , A61K39/008 , A61K39/04 , A61K39/145
摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
公开(公告)号：US20180236063A1
公开(公告)日：2018-08-23
申请号：US15875517
申请日：2018-01-19
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/39 , A61K39/008 , A61K39/145 , A61K39/00 , A61K39/04 , A61K39/35 , A61K9/107 , A61K45/06
摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
公开(公告)号：US20180221470A1
公开(公告)日：2018-08-09
申请号：US15823852
申请日：2017-11-28
发明人： Steven G. Reed , Darrick Carter
IPC分类号： A61K39/39 , A61K9/107 , A61K39/00 , A61K39/145 , A61K39/04 , A61K39/008 , A61K45/06 , A61K39/35
摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.035 秒)
